Sandoz, Teva Pharma plans to ramp up biosimilars production Ruchika Sharma23 Nov 2022 1:30 PM ISTTeva Chief Executive KÃ¥re Schultz said the company was targeting "80% of what's going off-patent in the next 10 years" including big sellers like the...
Merck lifts full-year forecast as cancer immunotherapy Keytruda sales soar Ruchika Sharma29 Oct 2022 1:30 PM ISTMerck has been looking to pursue deals to protect itself from an eventual revenue loss as Keytruda patents begin to expire toward the end of the...
Merck to develop personalized cancer vaccine in collaboration with Moderna Ruchika Sharma13 Oct 2022 12:15 PM ISTUnder the agreement, originally established in 2016 and amended in 2018, Merck will pay Moderna $250 million to exercise its option for personalized...
Merck Keytruda fails head and neck cancer trial Rahul Verma21 July 2022 5:00 PM ISTMerck, known as MSD outside the United States and Canada, has announced that the Phase 3 KEYNOTE-412 trial evaluating KEYTRUDA (pembrolizumab),...
Merck Keytruda fails in head and neck cancer trial Ruchika Sharma21 July 2022 2:30 PM ISTKEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and...
Merck in advanced talks to buy Seagen in nearly USD 40-billion deal: WSJ Ruchika Sharma10 July 2022 12:00 PM ISTThe companies are seeking to seal the deal on or before the announcement of Merck's second-quarter earnings set for July 28, according to the WSJ...
Merck seeks USFDA nod for Keytruda to treat non-small cell lung cancer Ruchika Sharma14 Jun 2022 12:00 PM ISTKEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and...
Merck KEYTRUDA gets European nod to treat Deficient Mismatch Repair tumors Ruchika Sharma2 May 2022 1:00 PM ISTKEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and...
Merck gets positive EU CHMP opinion for Keytruda for patients with MSI-H or dMMR tumors in five different types of cancer Ruchika Sharma28 March 2022 10:30 AM ISTKeytruda is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and...
Merck to stop Phase 3 KEYLYNK-010 trial investigating Combo therapy of KEYTRUDA and LYNPARZA MD Bureau18 March 2022 2:00 PM ISTMerck, known as MSD outside the United States and Canada, today announced that it will stop the Phase 3 KEYLYNK-010 trial investigating KEYTRUDA,...
Merck, Eisai get Japanese nod for cancer cocktail drug Keytruda, Lenvima Ruchika Sharma30 Dec 2021 12:22 PM ISTKenilworth: Merck, known as MSD outside the United States and Canada, and Eisai have announced that the Japanese Ministry of Health, Labour and...
Merck gets positive EU CHMP opinion for Keytruda as adjuvant therapy in RCC following surgery Medical Dialogues Bureau19 Dec 2021 10:00 AM ISTKenilworth: Merck known as MSD outside the United States and Canada, has announced the Committee for Medicinal Products for Human Use (CHMP) of the...
